Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — Shareholder Meeting (May 2024)
8 slides from Emergent Biosolutions's shareholder meeting presentation, May 29, 2024
Slide 1: Emergent BioSolutions 2024 Annual Meeting of Stockholders
PROPRIETARY AND CONFIDENTIAL Emergent BioSolutions M A Y 2 3 , 2 0 2 4 2 0 2 4 A N N U A L M E E T I N G O F S T O C K H O L D E R S
Slide 2: Agenda
PROPRIETARY AND CONFIDENTIAL • Call to Order; Rules and Procedure • Introductions • Procedural Matters; Declaration of Quorum • Presentation of the proposals to be considered and voted on by the stockholders as set forth in the proxy statement: o Proposal 1: to elect Donald DeGoyler, Neal Fowler, an
Slide 3: State of the Company
PROPRIETARY AND CONFIDENTIAL 3 J O S E P H PA PA P R E S I D E N T , C H I E F E X E C U T I V E O F F I C E R & D I R E C T O R State of the Company
Slide 4: Highlights of actions taken over the past year
Highlights of actions taken over the past year 4 Strengthened Portfolio • Approval and launch of over-the-counter NARCAN® Nasal Spray • New $379.6 million U.S. Dept. of Defense contract for RSDL® (Reactive Skin Decontamination Lotion) Kits • FDA approval of CYFENDUS® (formerly AV7909), a two-dose an
Slide 5: A multi-year plan to stabilize, turnaround and transform
A multi-year plan to stabilize, turnaround and transform 5 • Our mission is unchanged • Q1 2024 stabilization efforts and priorities: Continued focus on MCM and NARCAN® Nasal Spray as core business drivers Sharpened strategy on future growth drivers Leading with integrity through a culture of qualit
Slide 6: Preliminary Voting Results
PROPRIETARY AND CONFIDENTIAL 6 Preliminary Voting Results
Slide 7: Q&A
PROPRIETARY AND CONFIDENTIAL 7 Q&A 7
Slide 8: Forward-looking statements
PROPRIETARY AND CONFIDENTIAL This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our
Emergent BioSolutions — Shareholder Meeting (May 2024) on 6ix